BIOCRYST PHARMACEUTICALS INC's ticker is BCRX and the CUSIP is 09058V103. A total of 179 filers reported holding BIOCRYST PHARMACEUTICALS INC in Q4 2020. The put-call ratio across all filers is 1.12 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $140,892 | -9.9% | 19,900 | -10.4% | 0.01% | -9.1% |
| Q2 2023 | $156,288 | -15.6% | 22,200 | 0.0% | 0.01% | -15.4% |
| Q1 2023 | $185,148 | -27.4% | 22,200 | 0.0% | 0.01% | -35.0% |
| Q4 2022 | $254,856 | -9.0% | 22,200 | 0.0% | 0.02% | -13.0% |
| Q3 2022 | $280,000 | +18.6% | 22,200 | -0.4% | 0.02% | +21.1% |
| Q2 2022 | $236,000 | -52.9% | 22,300 | -27.6% | 0.02% | -44.1% |
| Q1 2022 | $501,000 | -1.8% | 30,800 | -16.3% | 0.03% | +3.0% |
| Q4 2021 | $510,000 | -6.8% | 36,800 | +2.0% | 0.03% | -15.4% |
| Q3 2021 | $547,000 | +69.3% | 36,065 | +76.8% | 0.04% | +56.0% |
| Q2 2021 | $323,000 | +41.7% | 20,400 | -8.9% | 0.02% | +13.6% |
| Q1 2021 | $228,000 | +36.5% | 22,400 | 0.0% | 0.02% | +29.4% |
| Q4 2020 | $167,000 | – | 22,400 | – | 0.02% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Burrage Capital Management LLC | 864,916 | $13,674,000 | 13.71% |
| Sarissa Capital Management LP | 4,261,000 | $67,366,000 | 5.36% |
| ORACLE INVESTMENT MANAGEMENT INC | 1,920,733 | $30,367,000 | 4.18% |
| HealthCor Management, L.P. | 3,248,100 | $51,352,000 | 2.05% |
| Parkman Healthcare Partners LLC | 351,961 | $5,565,000 | 1.22% |
| Bain Capital Public Equity Management II, LLC | 1,560,730 | $24,675,000 | 1.06% |
| Baker Brothers Advisors | 12,710,818 | $200,958,000 | 0.88% |
| DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C) | 2,835,000 | $44,821,000 | 0.80% |
| Biondo Investment Advisors, LLC | 265,840 | $4,203,000 | 0.72% |
| EAM Global Investors LLC | 157,065 | $2,483,000 | 0.69% |